Characteristics of a multigene assay (MammaPrint/Blueprint) to predict early recurrence of hormone receptor-positive, HER2-negative breast cancer: a case‒control study (WJOG16722B)

Breast Cancer · Published 2026-03-26 · DOI 10.1007/s12282-026-01847-2

Authors being retrieved — see the publisher record. https://doi.org/10.1007/s12282-026-01847-2

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2026

Related articles

Three cases of whole breast irradiation for breast cancer in patients with Lymphangioleiomyomatosis (LAM) · Breast Cancer · 2026 · Same journal
Low protein, high risk: hypoalbuminemia predicts adverse outcomes after mastectomy in 37,848 breast cancer patients · Breast Cancer · 2026 · Same journal
BRCA1/2 Reversion Mutations in Japanese Patients with Metastatic Breast Cancer Progressing on Olaparib: OLIVE (WJOG15321B) · Breast Cancer · 2026 · Same journal
Fear of diagnosis as a barrier to the screening and diagnosis of breast cancer · Breast Cancer · 2026 · Same journal
Quality of life in women with breast cancer undergoing chemotherapy: a comparative cross-sectional study of CICC ports and PICC-ports · Breast Cancer · 2026 · Same journal
Limits of substitution and context-dependent selective omission of Oncotype DX recurrence score testing · Breast Cancer · 2026 · Same journal
Breast ultrasound screening in young adult women undergoing infertility treatment at an infertility clinic: a retrospective observational study · Breast Cancer · 2026 · Same journal
Minimal important differences of EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: results from the RESQ trial · Breast Cancer · 2026 · Same journal
Comparison of three arm-positioning techniques for minimizing motion artifacts in breast magnetic resonance imaging: a prospective volunteer study · Breast Cancer · 2026 · Same journal
Low-progesterone receptor expression predicts nodal pathological complete response after neoadjuvant chemotherapy in premenopausal patients with ER-positive/HER2-negative breast cancer · Breast Cancer · 2026 · Same journal